Royal Bank Of Canada Ikena Oncology, Inc. Transaction History

Royal Bank Of Canada

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Nov 05, 2024	BUY	$1.27 - $2.0 $897 - $1,414	707 New	707 $1,000
Q1 2024 May 15, 2024	SELL	$1.27 - $2.0 $12,959 - $20,408	-10,204 Reduced 93.52%	707 $1,000
Q4 2023 Feb 14, 2024	BUY	$1.33 - $4.4 $8,816 - $29,167	6,629 Added 154.81%	10,911 $21,000
Q3 2023 Nov 14, 2023	BUY	$4.09 - $6.43 $6,728 - $10,577	1,645 Added 62.38%	4,282 $18,000
Q2 2023 Aug 14, 2023	BUY	$3.5 - $7.31 $8,302 - $17,339	2,372 Added 895.09%	2,637 $17,000
Q1 2023 May 15, 2023	BUY	$2.62 - $4.97 $694 - $1,317	265 New	265 $0
Q3 2022 Nov 14, 2022	BUY	$3.46 - $6.0 $124 - $216	36 Added 18.46%	231 $1,000
Q2 2022 Aug 15, 2022	SELL	$3.23 - $7.4 $4,867 - $11,151	-1,507 Reduced 88.54%	195 $1,000
Q1 2022 May 16, 2022	SELL	$5.61 - $13.85 $22,692 - $56,023	-4,045 Reduced 70.38%	1,702 $10,000
Q4 2021 Feb 14, 2022	BUY	$10.52 - $16.96 $44,731 - $72,113	4,252 Added 284.41%	5,747 $72,000
Q3 2021 Nov 15, 2021	BUY	$9.82 - $15.23 $8,582 - $13,311	874 Added 140.74%	1,495 $19,000
Q2 2021 Aug 16, 2021	BUY	$13.27 - $26.0 $8,240 - $16,146	621 New	621 $9,000

30.4M

Ticker IKNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,257,500
Market Cap $53.7M
Description
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.